PLTP activity inversely correlates with CAAD: Effects of PON1 enzyme activity and genetic variants on PLTP activity

Journal of Lipid Research

Volumn 56, Issue 7, 2015, Pages 1351-1362

  Kim, Daniel Seung ^a,b   Burt, Amber A ^a   Ranchalis, Jane E ^a   Vuletic, Simona ^a,c   Vaisar, Tomas ^a   Li, Wan Fen ^a   Rosenthal, Elisabeth A ^a   Dong, Weijiang ^a,c,d   Eintracht, Jason F ^e   Motulsky, Arno G ^a   Brunzell, John D ^a   Albers, John J ^a,c   Furlong, Clement E ^a   Jarvik, Gail P ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Northwest Lipid Metabolism and Diabetes Research Laboratories   (United States)

^d XI'AN JIAOTONG UNIVERSITY   (China)

^e VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Coronary artery disease; Paraoxonase 1; Phospholipid transfer protein

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL; ARYLDIALKYLPHOSPHATASE; LIPID; PON1 PROTEIN, HUMAN;

AGED; ARTICLE; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; ENZYME ACTIVITY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PCIF1 GENE; PLTP GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; BLOOD; ENZYMOLOGY; GENETICS; METABOLISM; MULTIVARIATE ANALYSIS;

AGED; ARYLDIALKYLPHOSPHATASE; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; LIPIDS; MALE; MULTIVARIATE ANALYSIS; PHOSPHOLIPID TRANSFER PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84937132734     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P058032     Document Type: Article

References (82)

1. Castelli, W. P. 1983. Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am. Heart J. 106: 1191-1200.
2. Acharjee, S., W. E. Boden, P. M. Hartigan, K. K. Teo, D. J. Maron, S. P. Sedlis, W. Kostuk, J. A. Spertus, M. Dada, B. R. Chaitman, et al. 2013. Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post-hoc analysis from the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). J. Am. Coll. Cardiol. 62: 1826-1833.
3. Boden, W. E., J. L. Probstfield, T. Anderson, B. R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, and W. Weintraub; AIM-HIGH Investigators. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365: 2255-2267.
4. Voight, B. F., G. M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, M. K. Jensen, G. Hindy, H. Hólm, E. L. Ding, T. Johnson, et al. 2012. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 380: 572-580.
5. El Harchaoui, K., B. J. Arsenault, R. Franssen, J-P. Després, G. K. Hovingh, E. S. G. Stroes, J. D. Otvos, N. J. Wareham, J. J. P. Kastelein, K-T. Khaw, et al. 2009. High-density lipoprotein particle size and concentration and coronary risk. Ann. Intern. Med. 150: 84-93.
6. Mackey, R. H., P. Greenland, D. C. Goff, D. Lloyd-Jones, C. T. Sibley, and S. Mora. 2012. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol. 60: 508-516.
7. Kim, D. S., A. A. Burt, E. A. Rosenthal, J. E. Ranchalis, J. F. Eintracht, T. S. Hatsukami, C. E. Furlong, S. Marcovina, J. J. Albers, and G. P. Jarvik. 2014. HDL-3 is a superior predictor of carotid artery disease in a case-control cohort of 1725 participants. J. Am. Heart Assoc. 3: e000902.
8. Kontush, A., S. Chantepie, and M. J. Chapman. 2003. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23: 1881-1888.
9. Jarvik, G. P., L. S. Rozek, V. H. Brophy, T. S. Hatsukami, R. J. Richter, G. D. Schellenberg, and C. E. Furlong. 2000. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler. Thromb. Vasc. Biol. 20: 2441-2447.
10. Jarvik, G. P., T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, and G. D. Schellenberg. 2003. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler. Thromb. Vasc. Biol. 23: 1465-1471.
11. Kim, D. S., A. A. Burt, J. E. Ranchalis, R. J. Richter, J. K. Marshall, J. F. Eintracht, E. A. Rosenthal, C. E. Furlong, and G. P. Jarvik. 2012. Additional common polymorphisms in the PON gene cluster predict PON1 activity but not vascular disease. J. Lipids. 2012: 476316.
12. Kim, D. S., D. R. Crosslin, P. L. Auer, S. M. Suzuki, J. Marsillach, A. A. Burt, A. S. Gordon, J. F. Meschia, M. A. Nalls, B. B. Worrall, et al; on behalf of the NHLBI Exome Sequencing Project. 2014. Rare coding variation in paraoxonase-1 is associated with ischemic stroke in the NHLBI Exome Sequencing Project. J. Lipid Res. 55: 1173-1178.
13. Hutchins, P. M., G. E. Ronsein, J. S. Monette, N. Pamir, J. Wimberger, Y. He, G. M. Anantharamaiah, D. S. Kim, J. E. Ranchalis, G. P. Jarvik, et al. 2014. Quantification of HDL particle concentration by calibrated ion mobility analysis. Clin. Chem. 60: 1393-1401.
14. Kim, D. S., P. M. Hutchins, and G. P. Jarvik. 2014. The HDL particle: frontiers for new discovery in cardioprotection. Clin. Lab. Int. 38: 16-19.
15. O'Brien, K. D., S. Vuletic, T. O. McDonald, G. Wolfbauer, K. Lewis, A-Y. Tu, S. Marcovina, T. N. Wight, A. Chait, and J. J. Albers. 2003. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation. 108: 270-274.
16. Desrumaux, C. M., P. A. Mak, W. A. Boisvert, D. Masson, D. Stupack, M. Jauhiainen, C. Ehnholm, and L. K. Curtiss. 2003. Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J. Lipid Res. 44: 1453-1461.
17. Cheung, M. C., and J. J. Albers. 2006. Active plasma phospholipid transfer protein is associated with apoA-I-but not apoE-containing lipoproteins. J. Lipid Res. 47: 1315-1321.
18. Oka, T., T. Kujiraoka, M. Ito, T. Egashira, S. Takahashi, M. N. Nanjee, N. E. Miller, J. Metso, V. M. Olkkonen, C. Ehnholm, et al. 2000. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J. Lipid Res. 41: 1651-1657.
19. Tall, A. R., S. Krumholz, T. Olivecrona, and R. J. Deckelbaum. 1985. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J. Lipid Res. 26: 842-851.
20. Bailey, D., I. Ruel, A. Hafiane, H. Cochrane, I. Iatan, M. Jauhiainen, C. Ehnholm, L. Krimbou, and J. Genest. 2010. Analysis of lipid transfer activity between model nascent HDL particles and plasma lipoproteins: implications for current concepts of nascent HDL maturation and genesis. J. Lipid Res. 51: 785-797.
21. Cheung, M. C., G. Wolfbauer, and J. J. Albers. 2011. Different phospholipid transfer protein complexes contribute to the variation in plasma PLTP specific activity. Biochim. Biophys. Acta. 1811: 343-347.
22. Wolfbauer, G., J. J. Albers, and J. F. Oram. 1999. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins. Biochim. Biophys. Acta. 1439: 65-76.
23. Chirackal Manavalan, A. P., A. Kober, J. Metso, I. Lang, T. Becker, K. Hasslitzer, M. Zandl, E. Fanaee-Danesh, J. B. Pippal, V. Sachdev, et al. 2014. Phospholipid transfer protein is expressed in cerebrovascular endothelial cells and involved in high density lipoprotein biogenesis and remodeling at the blood-brain barrier. J. Biol. Chem. 289: 4683-4698.
24. Albers, J. J., S. Vuletic, and M. C. Cheung. 2012. Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism. Biochim. Biophys. Acta. 1821: 345-357.
25. Jiang, X. C., S. Qin, C. Qiao, K. Kawano, M. Lin, A. Skold, X. Xiao, and A. R. Tall. 2001. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat. Med. 7: 847-852.
26. Lie, J., R. de Crom, T. van Gent, R. van Haperen, L. Scheek, F. Sadeghi-Niaraki, and A. van Tol. 2004. Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. J. Lipid Res. 45: 805-811.
27. Yang, X. P., D. Yan, C. Qiao, R. J. Liu, J-G. Chen, J. Li, M. Schneider, L. Lagrost, X. Xiao, and X-C. Jiang. 2003. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler. Thromb. Vasc. Biol. 23: 1601-1607.
28. Samyn, H., M. Moerland, T. van Gent, R. van Haperen, F. Grosveld, A. van Tol, and R. de Crom. 2009. Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice. Atherosclerosis. 204: 429-434.
29. Teslovich, T. M., K. Musunuru, A. V. Smith, A. C. Edmondson, I. M. Stylianou, M. Koseki, J. P. Pirruccello, S. Ripatti, D. I. Chasman, C. J. Willer, et al. 2010. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 466: 707-713.
30. Vergeer, M., S. M. Boekholdt, M. S. Sandhu, S. L. Ricketts, N. J. Wareham, M. J. Brown, U. de Faire, K. Leander, B. Gigante, M. Kavousi, et al. 2010. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease Susceptibility. Circulation. 122: 470-477.
31. Liu, R., M. R. Hojjati, C. M. Devlin, I. H. Hansen, and X. C. Jiang. 2007. Macrophage phospholipid transfer protein deficiency and ApoE secretion: impact on mouse plasma cholesterol levels and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27: 190-196.
32. Valenta, D. T., J. J. Bulgrien, D. J. Bonnet, and L. K. Curtiss. 2008. Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency. J. Lipid Res. 49: 24-32.
33. Valenta, D. T., N. Ogier, G. Bradshaw, A. S. Black, D. J. Bonnet, L. Lagrost, L. K. Curtiss, and C. M. Desrumaux. 2006. Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioscler. Thromb. Vasc. Biol. 26: 1572-1578.
34. Curtiss, L. K. 2006. What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler. Thromb. Vasc. Biol. 26: 12-19.
35. Robins, S. J., A. Lyass, R. W. Brocia, J. M. Massaro, and R. S. Vasan. 2013. Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study. Atherosclerosis. 228: 230-236.
36. Schlitt, A., C. Bickel, P. Thumma, S. Blankenberg, H. J. Rupprecht, J. Meyer, and X-C. Jiang. 2003. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 23: 1857-1862.
37. Schlitt, A., S. Blankenberg, C. Bickel, K. J. Lackner, G. H. Heine, M. Buerke, K. Werdan, L. Maegdefessel, U. Raaz, H. J. Rupprecht, et al. 2009. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study. J. Lipid Res. 50: 723-729.
38. Schgoer, W., T. Mueller, M. Jauhiainen, A. Wehinger, R. Gander, I. Tancevski, K. Salzmann, P. Eller, A. Ritsch, M. Haltmayer, et al. 2008. Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis. 196: 219-226.
39. Jarvik, G. P., R. Rajagopalan, E. A. Rosenthal, G. Wolfbauer, L. McKinstry, A. Vaze, J. Brunzell, A. G. Motulsky, D. A. Nickerson, P. J. Heagerty, et al. 2010. Genetic and nongenetic sources of variation in phospholipid transfer protein activity. J. Lipid Res. 51: 983-990.
40. Jarvik, G. P., N. T. Tsai, L. A. McKinstry, R. Wani, V. H. Brophy, R. J. Richter, G. D. Schellenberg, P. J. Heagerty, T. S. Hatsukami, and C. E. Furlong. 2002. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler. Thromb. Vasc. Biol. 22: 1329-1333.
41. Jarvik, G. P., R. Jampsa, R. J. Richter, C. S. Carlson, M. J. Rieder, D. A. Nickerson, and C. E. Furlong. 2003. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics. 13: 291-295.
42. Kim, D. S., A. A. Burt, J. E. Ranchalis, R. J. Richter, J. K. Marshall, K. S. Nakayama, E. R. Jarvik, J. F. Eintracht, E. A. Rosenthal, C. E. Furlong, et al. 2012. Dietary cholesterol increases paraoxonase 1 enzyme activity. J. Lipid Res. 53: 2450-2458.
43. Kim, D. S., S. K. Maden, A. A. Burt, J. E. Ranchalis, C. E. Furlong, and G. P. Jarvik. 2013. Dietary fatty acid intake is associated with paraoxonase 1 activity in a cohort-based analysis of 1,548 subjects. Lipids Health Dis. 12: 183.
44. Kim, D. S., A. A. Burt, J. E. Ranchalis, L. E. Jarvik, J. F. Eintracht, C. E. Furlong, and G. P. Jarvik. 2014. Effects of dietary components on high-density lipoprotein measures in a cohort of 1,566 participants. Nutr. Metab. (Lond). 11: 44.
45. Kim, D. S., A. A. Burt, D. R. Crosslin, P. D. Robertson, J. E. Ranchalis, E. J. Boyko, D. A. Nickerson, C. E. Furlong, and G. P. Jarvik. 2013. Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL. J. Lipid Res. 54: 552-560.
46. Kim, D. S., A. A. Burt, J. E. Ranchalis, E. R. Jarvik, E. A. Rosenthal, T. S. Hatsukami, C. E. Furlong, and G. P. Jarvik. 2013. Novel gene-by-environment interactions: APOB and NPC1L1 variants affect the relationship between dietary and total plasma cholesterol. J. Lipid Res. 54: 1512-1520.
47. Gunderson, K. L., F. J. Steemers, G. Lee, L. G. Mendoza, and M. S. Chee. 2005. A genome-wide scalable SNP genotyping assay using microarray technology. Nat. Genet. 37: 549-554.
48. Pritchard, J. K., M. Stephens, and P. Donnelly. 2000. Inference of population structure using multilocus genotype data. Genetics. 155: 945-959.
49. Howie, B. N., P. Donnelly, and J. Marchini. 2009. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5: e1000529.
50. Abecasis, G. R., A. Auton, L. D. Brooks, M. A. DePristo, R. M. Durbin, R. E. Handsaker, H. M. Kang, G. T. Marth, and G. A. McVean; 1000 Genomes Project Consortium. 2012. An integrated map of genetic variation from 1,092 human genomes. Nature. 491: 56-65.
51. Delaneau, O., J-F. Zagury, and J. Marchini. 2013. Improved whole-chromosome phasing for disease and population genetic studies. Nat. Methods. 10: 5-6.
52. Bachorik, P. S., and J. J. Albers. 1986. Precipitation methods for quantification of lipoproteins. Methods Enzymol. 129: 78-100.
53. Marcovina, S. M., J. J. Albers, L. O. Henderson, and W. H. Hannon. 1993. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin. Chem. 39: 773-781.
54. Cheung, M. C., B. G. Brown, E. K. Marino Larsen, A. D. Frutkin, K. D. O'Brien, and J. J. Albers. 2006. Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease. Biochim. Biophys. Acta. 1762: 131-137.
55. Cheung, M. C., G. Wolfbauer, and J. J. Albers. 1996. Plasma phospholipid mass transfer rate: relationship to plasma phospholipid and cholesteryl ester transfer activities and lipid parameters. Biochim. Biophys. Acta. 1303: 103-110.
56. Carlson, C. S., M. A. Eberle, M. J. Rieder, Q. Yi, L. Kruglyak, and D. A. Nickerson. 2004. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet. 74: 106-120.
57. Purcell, S., B. Neale, K. Todd-Brown, L. Thomas, M. A. R. Ferreira, D. Bender, J. Maller, P. Sklar, P. I. W. de Bakker, M. J. Daly, et al. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81: 559-575.
58. Ronald, J., R. Rajagopalan, J. E. Ranchalis, J. K. Marshall, T. S. Hatsukami, P. J. Heagerty, and G. P. Jarvik. 2009. Analysis of recently identified dyslipidemia alleles reveals two loci that contribute to risk for carotid artery disease. Lipids Health Dis. 8: 52.
59. Mihaylova, B., J. Emberson, L. Blackwell, A. Keech, J. Simes, E. H. Barnes, M. Voysey, A. Gray, R. Collins, and C. Baigent; Cholesterol Treatment Trialists' (CTT) Collaborators. 2012. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 380: 581-590.
60. Rohatgi, A., A. Khera, J. D. Berry, E. G. Givens, C. R. Ayers, K. E. Wedin, I. J. Neeland, I. S. Yuhanna, D. R. Rader, J. A. de Lemos, et al. 2014. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371: 2383-2393.
61. de Vries, R., G. M. Dallinga-Thie, A. J. Smit, B. H. R. Wolffenbuttel, A. van Tol, and R. P. F. Dullaart. 2006. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia. 49: 398-404.
62. Kim, D. S., J. Marsillach, C. E. Furlong, and G. P. Jarvik. 2013. Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics. 14: 1495-1515.
63. Bhattacharyya, T., S. J. Nicholls, E. J. Topol, R. Zhang, X. Yang, D. Schmitt, X. Fu, M. Shao, D. M. Brennan, and S. G. Ellis. 2008. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 299: 1265-1276.
64. Vaisar, T., S. Pennathur, P. S. Green, S. A. Gharib, A. N. Hoofnagle, M. C. Cheung, J. Byun, S. Vuletic, S. Kassim, P. Singh, et al. 2007. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117: 746-756.
65. Aviram, M., M. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo-Parmo, and B. N. La Du. 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101: 1581-1590.
66. Mackness, M. I., S. Arrol, C. Abbott, and P. N. Durrington. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104: 129-135.
67. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
68. Shih, D. M., L. Gu, Y-R. Xia, M. Navab, W-F. Li, S. Hama, L. W. Castellani, C. E. Furlong, L. G. Costa, A. M. Fogelman, et al. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284-287.
69. Shih, D. M., Y-R. Xia, X-P. Wang, E. Miller, L. W. Castellani, G. Subbanagounder, H. Cheroutre, K. F. Faull, J. A. Berliner, J. L. Witztum, et al. 2000. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275: 17527-17535.
70. Cheung, M. C., T. Vaisar, X. Han, J. W. Heinecke, and J. J. Albers. 2010. Phospholipid transfer protein in human plasma associates with proteins linked to immunity and inflammation. Biochemistry. 49: 7314-7322.
71. Vuletic, S., W. Dong, G. Wolfbauer, C. Tang, and J. J. Albers. 2011. PLTP regulates STAT3 and NFκB in differentiated THP1 cells and human monocyte-derived macrophages. Biochim. Biophys. Acta. 1813: 1917-1924.
72. Vuletic, S., B. A. Taylor, G. H. Tofler, A. Chait, S. M. Marcovina, K. Schenck, and J. J. Albers. 2008. SAA and PLTP activity in plasma of periodontal patients before and after full-mouth tooth extraction. Oral Dis. 14: 514-519.
73. Jänis, M. T., S. Siggins, E. Tahvanainen, R. Vikstedt, K. Silander, J. Metso, A. Aromaa, M-R. Taskinen, V. M. Olkkonen, M. Jauhiainen, et al. 2004. Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample. J. Lipid Res. 45: 2303-2309.
74. Settasatian, N., M. Duong, L. K. Curtiss, C. Ehnholm, M. Jauhiainen, J. Huuskonen, and K. A. Rye. 2001. The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J. Biol. Chem. 276: 26898-26905.
75. Oram, J. F., G. Wolfbauer, A. M. Vaughan, C. Tang, and J. J. Albers. 2003. Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells. J. Biol. Chem. 278: 52379-52385.
76. Sliwkowski, M. B., and H. G. Windmueller. 1984. Rat liver and small intestine produce proapolipoprotein A-I which is slowly processed to apolipoprotein A-I in the circulation. J. Biol. Chem. 259: 6459-6465.
77. Lee-Rueckert, M., R. Vikstedt, J. Metso, C. Ehnholm, P. T. Kovanen, and M. Jauhiainen. 2006. Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells. J. Lipid Res. 47: 1725-1732.
78. Kaess, B. M., M. Tomaszewski, P. S. Braund, K. Stark, S. Rafelt, M. Fischer, R. Hardwick, C. P. Nelson, R. Debiec, F. Huber, et al. 2011. Large-scale candidate gene analysis of HDL particle features. PLoS ONE. 6: e14529.
79. Chasman, D. I., G. Paré, S. Mora, J. C. Hopewell, G. Peloso, R. Clarke, L. A. Cupples, A. Hamsten, S. Kathiresan, A. Mälarstig, et al. 2009. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 5: e1000730.
80. Kathiresan, S., B. F. Voight, S. Purcell, K. Musunuru, D. Ardissino, P. M. Mannucci, S. Anand, J. C. Engert, N. J. Samani, H. Schunkert, et al. 2009. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat. Genet. 41: 334-341. [Erratum. 2009. Nat. Genet. 41: 762.]
81. Fan, H., K. Sakuraba, A. Komuro, S. Kato, F. Harada, and Y. Hirose. 2003. PCIF1, a novel human WW domain-containing protein, interacts with the phosphorylated RNA polymerase II. Biochem. Biophys. Res. Commun. 301: 378-385.
82. Liu, A., B. M. Desai, and D. A. Stoffers. 2004. Identification of PCIF1, a POZ domain protein that inhibits PDX-1 (MODY4) transcriptional activity. Mol. Cell. Biol. 24: 4372-4383.